Efficacy of Helicobacter pylori eradication quadruple therapy combined with Bifidobacterium in the treatment of Helicobacter pylori infection in adolescents
10.7619/jcmp.201803013
- VernacularTitle:双歧杆菌联合幽门螺杆菌根除四联疗法治疗青少年人群幽门螺旋杆菌感染的临床研究
- Author:
Zhihua ZHANG
1
;
Xiaohuan GONG
;
Jinfu MA
;
Qingsan YU
Author Information
1. 青海西宁富康医院消化内科
- Keywords:
Helicobacter pylori;
adolescents;
Bifidobacterium;
quadruple therapy;
eradication rate
- From:
Journal of Clinical Medicine in Practice
2018;22(3):48-50
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical efficacy of Helicobacter pylori (Hp) eradication quadruple therapy combined with Bifidobacterium in the treatment of Hp infection in adolescents.Methods A total of 180 outpatient or hospitalization adolescents with Hp infection in our hospital were randomly divided into Hp eradication quadruple therapy combined with Bifidobacterium group (treatment group,90 cases) and Hp eradication quadruple therapy group (control group,90 cases).The control group was given oral administration of pantoprazole,clarithromycin,amoxicillin,and bismuth potassium citrate,at dose of 40 mg,500 mg,1 000 mg,and 220 mg respectively,at 0.5 h after meal,for twice a day.The treatment group was treated with quadruple therapy plus Bifidobacterium triple viable capsule,at a dose of 630 mg,at 4 hours of morning and evening meals.The two groups were both treated for 14 days.Results The eradication rates of the treatment group and control group were 91.11％ and 62.2％,respectively (P ＜ 0.05).The adverse reactions were mild,including nausea,abdominal distension,diarrhea,constipation,bitter mouth,etc.,and their incidences in the treatment group and the control group was 6.67％ and 21.11％,respectively (P ＜ 0.05).Conclusion Hp eradication quadruple therapy combined with Bifidobacterium might improve the Hp eradication rate and reduce the incidence of adverse reactions in the treatment of Helicobacter pylori infection in adolescents.
